Akebia Therapeutics Inc. (AKBA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Akebia Therapeutics Inc. (AKBA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.93

0.04 (2.12%)

At close: Jan 15, 2025, 11:10 AM

undefined% (undefined)

Bid	1.92
Market Cap	420.00M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.22
PE Ratio (ttm)	-8.75
Forward PE	n/a
Analyst	Buy

Ask	1.93
Volume	1,072,010
Avg. Volume (20D)	2,249,014
Open	1.93
Previous Close	1.89
Day's Range	1.91 - 2.00
52-Week Range	0.80 - 2.48
Beta	undefined

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 20, 2014

Employees 167

Stock Exchange NASDAQ

Ticker Symbol AKBA

Website https://www.akebia.com

Analyst Forecast

According to 1 analyst ratings, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 289.61% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Akebia Therapeutics Inc. is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $40.91M, reflecting a -27.2% YoY shrinking and earnings per share of -0.04.

Why Price Moved

2 days ago · Source

+6.86%

Akebia Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

2 months ago · Source

-6.5%

Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

1 week ago · zacks.com

New Strong Sell Stocks for January 3rd

AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.

1 month ago · zacks.com

New Strong Sell Stocks for December 5th

AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.

1 month ago · zacks.com

New Strong Sell Stocks for November 27th

AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024.

1 month ago · zacks.com

New Strong Sell Stocks for November 22nd

ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.

1 month ago · seekingalpha.com

Q3 2024 Earnings: Hold Akebia Therapeutics

Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expandin...

2 months ago · seekingalpha.com

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief E...

2 months ago · zacks.com

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.